Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Preclinical target validation using patient-derived cells.

Literature DB >> 25722227

Preclinical target validation using patient-derived cells.

Aled M Edwards¹, Cheryl H Arrowsmith², Chas Bountra³, Mark E Bunnage⁴, Marc Feldmann⁵, Julian C Knight⁶, Dhavalkumar D Patel⁷, Panagiotis Prinos¹, Michael D Taylor⁸, Michael Sundström⁹.

Abstract

The Structural Genomics Consortium (SGC) and its clinical, industry and disease-foundation partners are launching open-source preclinical translational medicine studies.

Entities: Species

Mesh：

Year: 2015 PMID： 25722227 DOI： 10.1038/nrd4565

Source DB: PubMed Journal: Nat Rev Drug Discov ISSN： 1474-1776 Impact factor: 84.694

3 in total

1. Getting pharmaceutical R&D back on target.

Authors: Mark E Bunnage
Journal: Nat Chem Biol Date: 2011-06 Impact factor: 15.040

2. Why have clinical trials in sepsis failed?

Authors: John C Marshall
Journal: Trends Mol Med Date: 2014-02-24 Impact factor: 11.951

3. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis.

Authors: F M Brennan; D Chantry; A Jackson; R Maini; M Feldmann
Journal: Lancet Date: 1989-07-29 Impact factor: 79.321

3 in total

20 in total

1. Know your target, know your molecule.

Authors: Mark E Bunnage; Adam M Gilbert; Lyn H Jones; Erik C Hett
Journal: Nat Chem Biol Date: 2015-06 Impact factor: 15.040

Review 2. Opportunities and challenges in phenotypic drug discovery: an industry perspective.

Authors: John G Moffat; Fabien Vincent; Jonathan A Lee; Jörg Eder; Marco Prunotto
Journal: Nat Rev Drug Discov Date: 2017-07-07 Impact factor: 84.694

Review 3. Applications of chemogenomic library screening in drug discovery.

Authors: Lyn H Jones; Mark E Bunnage
Journal: Nat Rev Drug Discov Date: 2017-01-20 Impact factor: 84.694

Review 4. Screening out irrelevant cell-based models of disease.

Authors: Peter Horvath; Nathalie Aulner; Marc Bickle; Anthony M Davies; Elaine Del Nery; Daniel Ebner; Maria C Montoya; Päivi Östling; Vilja Pietiäinen; Leo S Price; Spencer L Shorte; Gerardo Turcatti; Carina von Schantz; Neil O Carragher
Journal: Nat Rev Drug Discov Date: 2016-09-12 Impact factor: 84.694

Preclinical target validation using patient-derived cells.

1. Getting pharmaceutical R&D back on target.

2. Why have clinical trials in sepsis failed?

3. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis.

1. Know your target, know your molecule.

Review 2. Opportunities and challenges in phenotypic drug discovery: an industry perspective.

Review 3. Applications of chemogenomic library screening in drug discovery.

Review 4. Screening out irrelevant cell-based models of disease.

Review 5. Predictive validity in drug discovery: what it is, why it matters and how to improve it.

Review 6. Using cultured endothelial cells to study endothelial barrier dysfunction: Challenges and opportunities.

Review 7. Reproducing the human mucosal environment ex vivo: inflammatory bowel disease as a paradigm.

Review 8. WD40 repeat domain proteins: a novel target class?

9. Assessing Specificity of Anticancer Drugs In Vitro.

Review 10. Review: in vitro microvessel models.